Systemic treatment in breast-cancer patients with brain metastasis

被引：41

作者：

Arslan, Cagatay ^{[1
]}

Dizdar, Omer ^{[1
]}

Altundag, Kadri ^{[1
]}

机构：

[1] Hacettepe Univ, Inst Oncol, Dept Med Oncol, TR-0000 Ankara, Turkey

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 07期

关键词：

CENTRAL-NERVOUS-SYSTEM; PHASE-II TRIAL; DOSE INTRAVENOUS METHOTREXATE; TEMOZOLOMIDE; WEEKS; PROGNOSTIC-FACTORS; SOLID TUMORS; CEREBROSPINAL-FLUID; RANDOMIZED-TRIAL; I/II TRIAL; LEPTOMENINGEAL METASTASIS;

D O I：

10.1517/14656561003702412

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Areas covered in this review: Standard therapy for brain metastasis is currently whole-brain radiotherapy. Other treatment modalities include surgery and radiosurgery in selected cases, corticosteroids, and systemic chemotherapy. Little progress has been made in chemotherapy for the treatment of brain metastases, partly because tumors develop brain metastases at a stage when they become totally chemoresistant. Nevertheless, new treatment choices have emerged considering cytotoxic and biological agents for the treatment of CNS metastases in patients with breast cancer. What the readers will gain: In this review, we aimed to review current and future treatment options in the systemic treatment of brain metastases of breast cancer. Take home message: Corticosteroids, anti-epileptic drugs, and radiotherapy remain the cornerstones of management. The efficacy of conventional cytotoxic chemotherapeutics is limited. Novel biologic agents, lapatinib being the most promising, are currently investigated in the treatment of brain metastases of breast cancer with promising results.

引用

页码：1089 / 1100

页数：12

共 103 条

[1]

A phase II trial of temozolomide for patients with recurrent or progressive brain metastases [J].

Abrey, LE ;

Olson, JD ;

Raizer, JJ ;

Mack, M ;

Rodavitch, A ;

Boutros, DY ;

Malkin, MG .

JOURNAL OF NEURO-ONCOLOGY, 2001, 53 (03) :259-265

[2]

Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases [J].

Addeo, Raffaele ;

De Rosa, Carmine ;

Faiola, Vincenzo ;

Leo, Luigi ;

Cennamo, Gregorio ;

Montella, Liliana ;

Guarrasi, Rosario ;

Vincenzi, Bruno ;

Caraglia, Michele ;

Del Prete, Salvatore .

CANCER, 2008, 113 (09) :2524-2531

[3]

Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis [J].

Altundag, Kadri ;

Bondy, Melissa L. ;

Mirza, Nadeern Q. ;

Kau, Shu-Wan ;

Broglio, Kristine ;

Hortobagyi, Gabriel N. ;

Rivera, Edgardo .

CANCER, 2007, 110 (12) :2640-2647

[4]

Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases [J].

Antonadou, D ;

Paraskevaidis, M ;

Sarris, G ;

Coliarakis, N ;

Economou, I ;

Karageorgis, P ;

Throuvalas, N .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3644-3650

[5]

Baker SD, 1996, CANCER CHEMOTH PHARM, V37, P195

[6]

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts [J].

Baschnagel, Andrew ;

Russo, Andrea ;

Burgan, William E. ;

Carter, Donna ;

Beam, Katie ;

Palmieri, Diane ;

Steeg, Patricia S. ;

Tofilon, Philip ;

Camphausen, Kevin .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (06) :1589-1595

[7]

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].

Bendell, JC ;

Domchek, SM ;

Burstein, HJ ;

Harris, L ;

Younger, J ;

Kuter, I ;

Bunnell, C ;

Rue, M ;

Gelman, R ;

Winer, E .

CANCER, 2003, 97 (12) :2972-2977

[8]

BRAIN METASTASES IN BREAST-CANCER - NATURAL-HISTORY, PROGNOSTIC FACTORS AND OUTCOME [J].

BOOGERD, W ;

VOS, VW ;

HART, AAM ;

BARIS, G .

JOURNAL OF NEURO-ONCOLOGY, 1993, 15 (02) :165-174

[9]

BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO

[10]

2-P

← 1 2 3 4 5 6 7 8 9 10 →